2009
DOI: 10.1161/circulationaha.108.843680
|View full text |Cite
|
Sign up to set email alerts
|

Hepatocyte Growth Factor or Vascular Endothelial Growth Factor Gene Transfer Maximizes Mesenchymal Stem Cell–Based Myocardial Salvage After Acute Myocardial Infarction

Abstract: Background-Mesenchymal stem cell (MSC)-based regenerative strategies were investigated to treat acute myocardial infarction and improve left ventricular function. Methods and Results-Murine AMI was induced by coronary ligation with subsequent injection of MSCs, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), or MSCs ϩHGF/VEGF into the border zone. Left ventricular ejection fraction was calculated using micro-computed tomography imaging after 6 months. HGF and VEGF protein injection (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
137
0
1

Year Published

2010
2010
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 196 publications
(144 citation statements)
references
References 30 publications
6
137
0
1
Order By: Relevance
“…MSC survival in vivo may be related to the ability of the stem cells to proliferate after transplantation in the heart. This hypothesis is supported by the observation that an increased proliferation of MSCs is associated with an improved myocardial function following chronic ischemia/infarction after stem cell treatment (10). While it is unlikely that proliferation occurs in the present model of acute I/R, the modulation of the TLR2 signaling pathway may be a potential strategy for optimizing the benefits of stem cell therapy for chronic myocardial ischemia.…”
Section: Discussionsupporting
confidence: 56%
See 1 more Smart Citation
“…MSC survival in vivo may be related to the ability of the stem cells to proliferate after transplantation in the heart. This hypothesis is supported by the observation that an increased proliferation of MSCs is associated with an improved myocardial function following chronic ischemia/infarction after stem cell treatment (10). While it is unlikely that proliferation occurs in the present model of acute I/R, the modulation of the TLR2 signaling pathway may be a potential strategy for optimizing the benefits of stem cell therapy for chronic myocardial ischemia.…”
Section: Discussionsupporting
confidence: 56%
“…Given the increasing evidence supporting the link of exogenous treatment with paracrine growth factors with improved myocardial function (3,18,22), it is reasonable to investigate the manipulation of MSCs to alter their production of paracrine factors. We and others have reported that MSCs can be altered to produce increased paracrine factors with associated improved myocardial function (10,19,41,43). We now add our observation that MSC TLR2 is beneficial in the acute setting for preischemic stem cell treatment of myocardial I/R and VEGF production.…”
Section: Discussionmentioning
confidence: 52%
“…HGF depletion has little effect on the in vivo efficacy of SHED-CM SHED-CM contains a variety of growth factors, including HGF (23). HGF is reported to promote angiogenesis and tissue regeneration and to suppress chronic inflammation in various disease models (31)(32)(33). Therefore, to determine whether the in vivo efficacy of SHED-CM is dependent on HGF, we treated EAE mice with HGF-depleted SHED-CM.…”
Section: Shed-cm Inhibits Mog 35-55 -Specific Cd4mentioning
confidence: 99%
“…Independently of the physiological or pathological state, VEGF is crucially involved in vascular endothelial function repairing and vascular regeneration (2,3). Previous studies have demonstrated that plasma VEGF levels are significantly elevated in patients with acute myocardial infarction (AMI) compared with those in healthy individuals (4)(5)(6)(7).…”
Section: Introductionmentioning
confidence: 99%